One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Advaxis logo
Advaxis ADXS
report update icon

Quarterly report 2023-Q3
added 05-16-2026

Advaxis Income Statement 2023-2002 | ADXS

Brief overview of profit and loss at Advaxis

The figures are compared over a five-year interval. According to figures from Advaxis, revenue changed from 6.1 million dollars to 13 thousand dollars over five years. The total change was −99.8%, with a CAGR of approximately −70.7%. The decline points to a contraction in the scale of the business.

The operating result measured by EBITDA moved from −$69.3 million to −$35.9 million, or +48.2%. Operating profitability strengthened faster than the scale of sales. EBITDA margin was −1142.4% at the start and −276130.8% at the end. The business retained less EBITDA from each unit of revenue.

The net financial result changed from −66.5 million dollars to −48.1 million dollars. Losses became smaller, but the business remains unprofitable.

Over the period, capitalization shifted from 783 million dollars to 1.9 million dollars (−99.8%). Investors remain cautious despite better financial results.

Overall conclusion

The financial trajectory is weak and requires a cautious interpretation. The strongest signals are improving net profitability. The overall view is constrained by lower investor confidence, a softer top-line trend and pressure on operating profitability. The key question is whether sales can be converted into sustainable profit.

Annual Income Statement Advaxis

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002

Market Cap

1.87 M 897 K 20.1 M 1.7 B 1.04 B 783 M 138 B 304 B 338 B 164 B 25.5 B 11.5 B 5.26 T - - - - - - - - -

Shares

6.02 M 2.9 M 1.61 M 61 M 15.2 M 3.43 M 40.5 M 35.4 M 28 M 17.1 M 5.01 M 2.56 M 223 M 151 M - - - - - - - -

Historical Prices

0.31 0.31 12.4 27.9 68.6 228 3.41 K 8.59 K 12.1 K 9.61 K 5.09 K 4.5 K 23.6 K - - - - - - - - -

Net Income

-48.1 M -38 M -17.9 M -26.5 M -16.6 M -66.5 M -93.4 M -73.6 M -47 M -16.5 M -20 M -12.1 M -8.12 M -10.8 M 929 K -5.42 M -2.45 M -6.2 M -1.81 M -538 K -910 K -167 K

Revenue

13 K 692 K 3.24 M 253 K 20.9 M 6.06 M 12 M 3.99 M - 1 M - - - - - - - - - - - -

Cost of Revenue

13 K 602 K - - - - - - - - - - - - - - - - - - - -

Gross Profit

- 90 K - 253 - - - - - - - - - - - - - - - - - -

Operating Income

-36.3 M -37.5 M -18.8 M -26.4 M -18 M -70.4 M -98.4 M -76.5 M -48.7 M -19.5 M -14.7 M -12.3 M -13 M -7.93 M - - - - - - - -

Interest Expense

28 K 74 K -1 K - -7 K -63 K -82 K -201 -6.6 K 5.25 K 988 K 4.54 M 4.7 M 3.81 M - - - - - - - -

EBITDA

-35.9 M -37.3 M -18.4 M -25.6 M -16.9 M -69.3 M -97.7 M -76.2 M -48.6 M -19.4 M -14.5 M -12.2 M -12.9 M -7.83 M - - - - - - - -

Operating Expenses

- 19.6 M 22 M 26.7 M 38.9 M 76.4 M 110 M 80.5 M 48.7 M 20.5 M 14.7 M 12.3 M 13 M 8.43 M - - - - - - - -

General and Administrative Expenses

12.2 M 9.74 M 11.5 M 11.1 M 12.2 M 19.5 M 40 M 31.7 M 24.2 M 11.7 M 9.07 M 5.69 M 4.94 M 3.53 M - - - - - - - -

All numbers in USD currency

Quarterly Income Statement Advaxis

2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

4.78 M 4.78 M 4.41 M 2.7 M 1.82 M 1.82 M 146 M 83.9 M 146 M 123 M 83.9 M 51.7 M 61.6 M 60.6 M 51.7 M 4.64 M 9.87 M 5.9 M 69.6 M 41.4 M 52.7 M 49.9 M 41.4 M 40.1 M 40.6 M 40.3 M 40.1 M 33.7 M 34.4 M 34.1 M 33.7 M 21.6 M 31 M 26.7 M 21.6 M 13.8 M 19.3 M 15.7 M 13.8 M 3.57 M 4.78 M 529 M 446 M 263 M 347 M 285 M 263 M 207 M 228 M 228 M 213 M

Net Income

-7.34 M -8.7 M -7.36 M -365 K -6.96 M -2.44 M -365 K -3.98 M -3.33 M -5.11 M -3.98 M -7.86 M -5.83 M -6.32 M -7.86 M 12.8 M -9.86 M -9.38 M 12.8 M -20.5 M -14 M -13.4 M -20.5 M -17.1 M -32.6 M -20.5 M -17.1 M -19.8 M -16.5 M -15.5 M -19.8 M -7.03 M -13.6 M -13.9 M -7.03 M -5.19 M -5.78 M -2.31 M -5.19 M -5.71 M -1.6 M -5.28 M -5.71 M -4.37 M -3.1 M -2.61 M -4.37 M 757 K 3.64 M 3.64 M -9.64 M

Revenue

13 K 9 K 4 K - 250 K 250 K 1.62 M 1.62 M 250 K 1.38 M 1.62 M 3 K 253 K 250 K 3 K 19.7 M 6 K 1.19 M 19.7 M 2.06 M 1.13 M 1.75 M 1.75 M 3.79 M 10.3 M 3.05 M 3.43 M 250 K 250 K 250 K - - - - - - 1 M 1 M 1 M - - - - - - - - - - - -

Cost of Revenue

13 K 9 K 4 K - 91 K 38 K 368 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

90 K 90 K 90 K - - - 90 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-7.13 M -8.49 M -11.9 M -4.16 M -7.29 M -3 M -4.16 M -3.96 M -4.13 M -6.32 M -3.96 M -7.89 M -5.84 M -6.32 M -7.89 M 10.3 M -10.1 M -7.87 M 10.3 M -20.5 M -14.2 M -13.6 M -20.5 M -17.2 M -32.8 M -20.7 M -17.2 M -20 M -16.6 M -15.6 M -20 M -6.78 M -13.6 M -13.8 M -6.78 M -5.96 M -6 M -2.6 M -5.96 M -2.18 M -3.05 M -5.48 M -2.18 M -3.24 M 3.58 M -3.23 M -3.24 M -2.97 M -3.6 M -3.6 M -3.41 M

Interest Expense

- - - -4 K 2 K -1 K -4 K 12 K 229 K 229 K 217 K - -2 K -1 K -4 K -4 K -7 K -2 K -4 K -35 K -2 K -5.71 K -34.5 K -123 -75 K -123 -123 -4 -201 -197 -4 6.24 K 5.25 K 3.24 K 2.02 K 2.02 K 5.25 K 3.24 K 2.02 K 361 K 143 K 96 K 361 K 1.62 M 1.05 M 1.58 M 1.62 M 532 K 1.77 M 1.77 M 419 K

EBITDA

-6.99 M -8.39 M -11.8 M -4.15 M -7.28 M -2.99 M -4.15 M -3.77 M -4.08 M -6.22 M -3.77 M -7.66 M -5.64 M -6.12 M -7.66 M 10.6 M -9.83 M -7.57 M 10.6 M -20.3 M -13.9 M -13.3 M -20.3 M -17 M -32.6 M -20.5 M -17 M -19.9 M -16.5 M -15.5 M -19.9 M -6.77 M -13.6 M -13.8 M -6.77 M -5.92 M -5.95 M -2.55 M -5.92 M -2.14 M -3.01 M -5.44 M -2.14 M -3.21 M 3.62 M -3.16 M -3.21 M -2.94 M -3.5 M -3.56 M -3.38 M

Operating Expenses

- - - 4.16 M 7.29 M 3.25 M 4.16 M 5.58 M 4.38 M 7.7 M 5.58 M 7.89 M 5.84 M 6.57 M 7.89 M 9.37 M 10.1 M 9.06 M 9.37 M 22.6 M 15.3 M 15.3 M 22.6 M 21 M 35.9 M 24.1 M 21 M 20.2 M 16.6 M 15.6 M 20.2 M 6.78 M 13.6 M 13.8 M 6.78 M 5.96 M 6 M 3.6 M 5.96 M 2.18 M 3.05 M 5.48 M 2.18 M 3.24 M 3.58 M 3.23 M 3.24 M 2.97 M 3.6 M 3.6 M 3.41 M

General and Administrative Expenses

1.45 M 2.76 M 4.6 M 2.51 M 2.05 M 1.77 M 2.51 M 3.01 M 2.68 M 3.35 M 3.01 M 3.03 M 2.38 M 2.65 M 3.03 M 2.67 M 3.08 M 3.09 M 2.67 M 5.85 M 4.5 M 4.47 M 5.53 M 7.33 M 18.1 M 7.78 M 7.33 M 7.14 M 6.42 M 6.83 M 7.14 M 3.15 M 6.34 M 7.7 M 3.2 M 4.4 M 2.99 M 2.05 M 4.4 M 1.2 M 1.73 M 3.36 M 1.2 M 1.03 M 2.25 M 1.01 M 1.03 M 982 K 1.64 M 1.64 M 962 K

All numbers in USD currency

The income statement is one of the three key financial reports of a company Advaxis (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
ММЦБ ММЦБ
GEMA
- - - russiaRussia
Lyra Therapeutics Lyra Therapeutics
LYRA
- - $ 24.9 M usaUSA
ОЗОН Фармацевтика ОЗОН Фармацевтика
OZPH
- - - russiaRussia
Промомед Промомед
PRMD
- - - russiaRussia
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
ESSA Pharma ESSA Pharma
EPIX
- - $ 8.86 M canadaCanada
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
- - $ 25.3 M usaUSA
Merus N.V. Merus N.V.
MRUS
- - $ 5.78 B niderlandNiderland
RAPT Therapeutics RAPT Therapeutics
RAPT
- - $ 2.36 B usaUSA
Annexon Annexon
ANNX
$ 4.21 4.99 % $ 653 M usaUSA
AbbVie AbbVie
ABBV
$ 291.22 1.06 % $ 515 B usaUSA
22nd Century Group 22nd Century Group
XXII
$ 1.56 -19.17 % $ 287 K usaUSA
Axon Enterprise Axon Enterprise
AXON
$ 313.68 -18.01 % $ 24.5 B usaUSA
Biogen Biogen
BIIB
$ 248.51 1.88 % $ 36.4 B usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 1.73 -2.15 % $ 4.26 B israelIsrael
Theratechnologies Theratechnologies
THTX
- - $ 83.9 M canadaCanada
Exelixis Exelixis
EXEL
$ 69.55 1.22 % $ 18.9 B usaUSA
Geron Corporation Geron Corporation
GERN
$ 0.99 3.97 % $ 660 M usaUSA
Gilead Sciences Gilead Sciences
GILD
$ 166.9 -0.4 % $ 208 B usaUSA
Grifols, S.A. Grifols, S.A.
GRFS
$ 8.46 -0.12 % $ 5.75 B spainSpain
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
$ 155.97 -0.44 % $ 20.4 B usaUSA
InflaRx N.V. InflaRx N.V.
IFRX
$ 1.31 -3.69 % $ 88.1 M germanyGermany
INmune Bio INmune Bio
INMB
$ 1.12 -4.68 % $ 27.7 M usaUSA
Insmed Incorporated Insmed Incorporated
INSM
$ 114.55 5.32 % $ 22.8 B usaUSA
Johnson & Johnson Johnson & Johnson
JNJ
$ 274.89 0.95 % $ 662 B usaUSA
Titan Pharmaceuticals Titan Pharmaceuticals
TTNP
- -3.76 % $ 3.47 M usaUSA
Lineage Cell Therapeutics Lineage Cell Therapeutics
LCTX
$ 1.02 3.75 % $ 235 M usaUSA
BioVie BioVie
BIVI
$ 1.33 9.92 % $ 1.96 M usaUSA
Longeveron Longeveron
LGVN
$ 1.82 6.43 % $ 32 B usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
TCR2 Therapeutics TCR2 Therapeutics
TCRR
- - $ 58.1 M usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
$ 84.95 0.13 % $ 7.99 B usaUSA
Mustang Bio Mustang Bio
MBIO
$ 0.39 0.15 % $ 1.91 M usaUSA
TFF Pharmaceuticals TFF Pharmaceuticals
TFFP
- -60.05 % $ 125 K usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 1.63 1.87 % $ 2.68 M israelIsrael
Mesoblast Limited Mesoblast Limited
MESO
$ 14.26 1.13 % $ 17.2 B australiaAustralia
Mirum Pharmaceuticals Mirum Pharmaceuticals
MIRM
$ 93.81 0.28 % $ 4.71 B usaUSA
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
- - $ 521 M usaUSA
Codexis Codexis
CDXS
$ 1.09 6.37 % $ 95 M usaUSA
MannKind Corporation MannKind Corporation
MNKD
$ 3.91 4.0 % $ 1.2 B usaUSA
MediciNova MediciNova
MNOV
$ 1.44 -0.69 % $ 70.7 M usaUSA
Axcella Health Axcella Health
AXLA
- -16.42 % $ 249 M usaUSA
Merck & Co. Merck & Co.
MRK
$ 146.81 -0.07 % $ 367 B usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
Tyme Technologies Tyme Technologies
TYME
- 8.07 % $ 54 M usaUSA
Curis Curis
CRIS
$ 0.88 3.67 % $ 11.6 M usaUSA